Deutsche Bank initiated coverage of Achillion Pharmaceuticals Inc. (ACHN) Wednesday morning, with a "Buy" rating.
Achillion Pharmaceuticals has gapped open sharply higher this morning and is now up 1.42 at $9.52 on above average volume. The stock has been rising for over a month and has set a 5-month high.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org